[A17-27] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 15.09.2017
Commission awarded on 15.06.2017 by the Federal Joint Committee (G-BA).
Treatment-naive adult patients with advanced (unresectable or metastatic) BRAF V600 WT melanoma
Hint of lesser benefit of nivolumab + ipilimumab versus nivolumab
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.